[1] Wang ZF, Liu ZH, Wang WY, et al. Two common mutations within CYP2C19 affected platelet aggregation in chinese patients undergoing PCI: A one-year follow-up study[J]. The Pharmacogenomics Journal,2019,19(2):157. [2] Zeb I, Krim N, Bella J. Role of CYP2C19 genotype testing in clinical use of clopidogrel: Is it really useful[J]. Expert Review of Cardiovascular Therapy,2018,16(5):369. [3] 柴永宏, 高敏, 焦玉壮. 脑血管病的遗传流行病学研究[J]. 中国临床神经科学,2018, 26(5):41. [4] 中华医学会神经病学分会,中华医学会神经病学分会脑血管病学组.中国脑血管疾病分类2015[J]. 中华神经科杂志,2017,50(2):168. [5] Yu S, Su Z, Miao J, et al. Different types of family history of stroke and stroke risk: results based on 655, 552 individuals[J]. Journal of Stroke and Cerebrovascular Diseases: the Official Journal of National Stroke Association,2018,10(1):10. [6] Martis S, Peter I, Hulot JS, et al. Multi-ethnic distribution of clinically relevant CYP2C genotypes and haplotypes[J]. Pharmacogenomics, 2013,13(4):369. [7] Hollopeter G, Jantzen HM, Vincent D, et al. Identification of platelet ADP receptor targeted by antithrombotic drugs[J]. Nature,2001,409 (6817):202. [8] Hu Y, Li Z, Shi W, et al. Early diagnosis of cerebral thrombosis by EGFP-EGF1 protein conjugated ferroferric oxide magnetic nanoparticles [J]. Biomater Appl, 2019,33:1195. [9] Fan DJ, Li CY, Chen J. Correlation between CYP2C19 gene polymorphism and elderly cerebral infarction[J]. Acta Academiae Medicinae Sinicae, 2018, 40(6):765. [10] Fujikura K, Ingelman-Sundberg M. Genetic variation in the human cytochrome P450 supergene family[J]. Pharmacogenetics and Genomics,2015, 25(12):584. [11] Thomalla G, Simonsen CZ, Boutitie F, et al. MRI-Guided thrombolysis for stroke with unknown time of onset[J]. The New England Journal of Medicine, 2018,379(7):611. [12] Morotti A, Poli L. Acute stroke[J]. Seminars in Neurology, 2019,39(1):61. [13] Rodrguez-Gonzlez F, Martnez-Quintana E, Saavedra P, et al. CYP2C19 or CYP3A5 genotyping does not predict clinical response to clopidogrel[J]. Journal of Clinical Pharmacology, 2018, 58(10):1274. [14] Lin J, Han Z, Wang C, et al. Dual therapy with clopidogrel and aspirin prevents early neurological deterioration in ischemic stroke patients carrying CYP2C19*2 reduced- function alleles[J]. European Journal of Clinical Pharmacology,2018,74(9):1131. [15] Arya V, Mahajan P, Saraf A, et al.Association of CYP2C19, CYP3A5 and GPIIb/IIIa gene polymorphisms with Aspirin and Clopidogrel resistance in a cohort of Indian patients with coronary artery disease[J].Int J Lab Hematol,2015,37:809. [16] Verschuren JJ, Trompet S, Wessels JA, et al.A systematic review on pharmacogenetics in cardiovascular disease: Is it ready for clinical application?[J]. Eur Heart J,2012,33:165. |